OBJECTIVES: The severe forms of hypertriglyceridaemia (HTG) are caused by mutations in genes that lead to the loss of function of lipoprotein lipase (LPL). In most patients with severe HTG (TG > 10 mmol L(-1) ), it is a challenge to define the underlying cause. We investigated the molecular basis of severe HTG in patients referred to the Lipid Clinic at the Academic Medical Center Amsterdam. METHODS: The coding regions of LPL, APOC2, APOA5 and two novel genes, lipase maturation factor 1 (LMF1) and GPI-anchored high-density lipoprotein (HDL)-binding protein 1 (GPIHBP1), were sequenced in 86 patients with type 1 and type 5 HTG and 327 controls. RESULTS: In 46 patients (54%), rare DNA sequence variants were identified, comprising variants in LPL (n = 19), APOC2 (n = 1), APOA5 (n = 2), GPIHBP1 (n = 3) and LMF1 (n = 8). In 22 patients (26%), only common variants in LPL (p.Asp36Asn, p.Asn318Ser and p.Ser474Ter) and APOA5 (p.Ser19Trp) could be identified, whereas no mutations were found in 18 patients (21%). In vitro validation revealed that the mutations in LMF1 were not associated with compromised LPL function. Consistent with this, five of the eight LMF1 variants were also found in controls and therefore cannot account for the observed phenotype. CONCLUSIONS: The prevalence of mutations in LPL was 34% and mostly restricted to patients with type 1 HTG. Mutations in GPIHBP1 (n = 3), APOC2 (n = 1) and APOA5 (n = 2) were rare but the associated clinical phenotype was severe. Routine sequencing of candidate genes in severe HTG has improved our understanding of the molecular basis of this phenotype associated with acute pancreatitis and may help to guide future individualized therapeutic strategies.
OBJECTIVES: The severe forms of hypertriglyceridaemia (HTG) are caused by mutations in genes that lead to the loss of function of lipoprotein lipase (LPL). In most patients with severe HTG (TG > 10 mmol L(-1) ), it is a challenge to define the underlying cause. We investigated the molecular basis of severe HTG in patients referred to the Lipid Clinic at the Academic Medical Center Amsterdam. METHODS: The coding regions of LPL, APOC2, APOA5 and two novel genes, lipase maturation factor 1 (LMF1) and GPI-anchored high-density lipoprotein (HDL)-binding protein 1 (GPIHBP1), were sequenced in 86 patients with type 1 and type 5 HTG and 327 controls. RESULTS: In 46 patients (54%), rare DNA sequence variants were identified, comprising variants in LPL (n = 19), APOC2 (n = 1), APOA5 (n = 2), GPIHBP1 (n = 3) and LMF1 (n = 8). In 22 patients (26%), only common variants in LPL (p.Asp36Asn, p.Asn318Ser and p.Ser474Ter) and APOA5 (p.Ser19Trp) could be identified, whereas no mutations were found in 18 patients (21%). In vitro validation revealed that the mutations in LMF1 were not associated with compromised LPL function. Consistent with this, five of the eight LMF1 variants were also found in controls and therefore cannot account for the observed phenotype. CONCLUSIONS: The prevalence of mutations in LPL was 34% and mostly restricted to patients with type 1 HTG. Mutations in GPIHBP1 (n = 3), APOC2 (n = 1) and APOA5 (n = 2) were rare but the associated clinical phenotype was severe. Routine sequencing of candidate genes in severe HTG has improved our understanding of the molecular basis of this phenotype associated with acute pancreatitis and may help to guide future individualized therapeutic strategies.
Authors: Philippa J Talmud; Emma Hawe; Steve Martin; Michael Olivier; George J Miller; Edward M Rubin; Len A Pennacchio; Steve E Humphries Journal: Hum Mol Genet Date: 2002-11-15 Impact factor: 6.150
Authors: Remco Franssen; Stephen G Young; Frank Peelman; Jozef Hertecant; Jeroen A Sierts; Alinda W M Schimmel; André Bensadoun; John J P Kastelein; Loren G Fong; Geesje M Dallinga-Thie; Anne P Beigneux Journal: Circ Cardiovasc Genet Date: 2010-02-02
Authors: Amit R Rahalkar; Fiona Giffen; Bryan Har; Josephine Ho; Katherine M Morrison; John Hill; Jian Wang; Robert A Hegele; Tisha Joy Journal: Can J Physiol Pharmacol Date: 2009-03 Impact factor: 2.273
Authors: William K Sonnenburg; Daiguan Yu; E-Chiang Lee; Wei Xiong; Gennady Gololobov; Billie Key; Jason Gay; Nat Wilganowski; Yi Hu; Sharon Zhao; Matthias Schneider; Zhi-Ming Ding; Brian P Zambrowicz; Greg Landes; David R Powell; Urvi Desai Journal: J Lipid Res Date: 2009-06-21 Impact factor: 5.922
Authors: Anne P Beigneux; Peter Gin; Brandon S J Davies; Michael M Weinstein; André Bensadoun; Loren G Fong; Stephen G Young Journal: J Biol Chem Date: 2009-09-02 Impact factor: 5.157
Authors: Anne P Beigneux; Remco Franssen; André Bensadoun; Peter Gin; Kristan Melford; Jorge Peter; Rosemary L Walzem; Michael M Weinstein; Brandon S J Davies; Jan A Kuivenhoven; John J P Kastelein; Loren G Fong; Geesje M Dallinga-Thie; Stephen G Young Journal: Arterioscler Thromb Vasc Biol Date: 2009-03-19 Impact factor: 8.311
Authors: Jun Eguchi; Kazuya Miyashita; Isamu Fukamachi; Katsuyuki Nakajima; Masami Murakami; Yuko Kawahara; Toru Yamashita; Yasuyuki Ohta; Koji Abe; Atsuko Nakatsuka; Mai Mino; Satoru Takase; Hiroaki Okazaki; Robert A Hegele; Michael Ploug; Xuchen Hu; Jun Wada; Stephen G Young; Anne P Beigneux Journal: J Clin Lipidol Date: 2018-10-24 Impact factor: 4.766
Authors: Xuchen Hu; Geesje M Dallinga-Thie; G Kees Hovingh; Sandy Y Chang; Norma P Sandoval; Tiffany Ly P Dang; Isamu Fukamachi; Kazuya Miyashita; Katsuyuki Nakajima; Masami Murakami; Loren G Fong; Michael Ploug; Stephen G Young; Anne P Beigneux Journal: J Clin Lipidol Date: 2017-06-13 Impact factor: 4.766
Authors: Wanee Plengpanich; Stephen G Young; Weerapan Khovidhunkit; André Bensadoun; Hirankorn Karnman; Michael Ploug; Henrik Gårdsvoll; Calvin S Leung; Oludotun Adeyo; Mikael Larsson; Suwanna Muanpetch; Supannika Charoen; Loren G Fong; Sathit Niramitmahapanya; Anne P Beigneux Journal: J Biol Chem Date: 2014-05-20 Impact factor: 5.157